PET/CT with various radiopharmaceuticals in the complex diagnosis of medullary thyroid carcinoma: a review-Reference-Cited by-同舟云学术

PET/CT with various radiopharmaceuticals in the complex diagnosis of medullary thyroid carcinoma: a review

Published:2023-07-05 Issue:2 Volume:14 Page:31-41
ISSN:2079-5343
Container-title:Diagnostic radiology and radiotherapy
language:
Short-container-title:Lučevaâ diagn. ter.

Author:

Tsentr N. V.¹^ORCID,Ertman A. E.¹,Ryzhkova D. V.¹^ORCID

Affiliation:

1. Almazov National Medical Research Centre

Abstract

INTRODUCTION: Medullary carcinoma is a rare malignant neuroendocrine tumor of the thyroid gland. Medullary thyroid carcinoma (MTC) has no specific clinical symptoms. Due to the absence of specific symptoms, the disease is usually diagnosed at the stage of metastatic lesions of regional lymph nodes, and sometimes, internal organs. The five- and ten-year survival after detection of distant metastases is 25% and 10%, respectively.OBJECTIVE: To analyze the available foreign and domestic literature to determine the role of PET/CT with various radiopharmaceuticals in the complex radiological diagnosis of MTC.MATERIALS AND METHODS: A search was made for scientific publications and clinical recommendations in the information and analytical systems PudMed, elibrary over the past ten years, dedicated to the diagnosis of MTC, including PET/CT with 18F-DOPA, 18F-FDG, 68Ga-DOTA peptides, etc. by keywords «medullary thyroid cancer», «medullary thyroid carcinoma», «PET/CT», «18F-L-dihydroxyphenylalanine», «18F-DOPA», «18F-DOPA», «68Ga-DOTA peptides», «68Ga-DOTA-peptides», «theranostics», «theranostics».RESULTS: The analysis of publications demonstrated the prospects for the use of PET/CT with various radiopharmaceuticals for the diagnosis of recurrent tumors and the prevalence of the process in biochemical recurrence of MTC, as well as the possibility of peptide-receptor radionuclide therapy for the treatment of advanced forms of the disease. The choice of radiopharmaceuticals is based on the results of laboratory diagnostics and conventional methods of anatomical imaging. PET/CT with 68Ga-DOTA peptides is performed to predict the effectiveness of peptide-receptor radionuclide therapy.CONCLUSION: PET/CT with various radiopharmaceuticals makes a significant contribution to the diagnosis of recurrent tumors, assessment of the prevalence of the tumor process and selection of patients for peptide-receptor radionuclide therapy.

Publisher

Baltic Medical Education Center

Subject

General Medicine

Reference54 articles.

1. Kondratovich V.A., Zhukovets A.G., Leonova T.A. Clinical and epidemiological characteristics and prognosis of the course of medullary thyroid cancer. Oncology journal, 2021, Vol. 15, No. 2, рр. 13–18 (In Russ.)].

2. Kuz’minov A.E., Polozkova S.A., Orel N.F., Gorbunova V.A. Neuroendocrine tumors. Effective pharmacotherapy, 2012, No. 34, рр. 44–48 (In Russ.)].

3. Ryzhkova D.V., Tikhonova D.N., Grineva E.N. Methods of nuclear medicine in the diagnosis of neuroendocrine tumors. Siberian journal of oncology, 2013, No. 1 (6), рр. 56–63 (In Russ.)].

4. Pinskiy S.B., Beloborodov V.A., Dvornichenko V.V., Batoroev Yu.K. Hereditary medullary thyroid cancer. Povolzhsky Oncological Bulletin, 2019, Vol. 10, No. 3, рр. 33–39 (In Russ.)].

5. Schlumberger M., Bastholt L., Dralle H., Jarzab B., Pacini F., Smit J.W.A. 2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer // European Thyroid Journal. 2012. Vol. 1, No. 1. P. 5–14. https://doi.org/10.1159/000336977.